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Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the 
Lynch Syndrome tumor spectrum
Dear Editor,
Lynch Syndrome (LS) is the most common hereditary cancer syndrome. It results from 
heterozygous pathogenic germline variants in the mismatch repair (MMR) genes that are carried 
by over 1 in 200 individuals. Pathogenic variants in each of the MMR genes, path_MLH1, 
path_MSH2, path_MSH6, and path_PMS2, result in different risks for cancers in organs including 
the colorectum, endometrium, ovaries, stomach, small bowel, bile duct, pancreas and upper urinary 
tract 1. These cancers, but not sarcomas, are commonly cited as LS spectrum cancers. Sarcomas 
include osteosarcomas (OS) that have a worldwide incidence of 4.3 per million in males and 3.4 
per million females per year 2, and soft tissue sarcomas (STS) that are a heterogeneous group of 
cancers of mesenchymal origin with a population incidence of 3.5 per 100,000 people per year in 
the US 3. In the most recent study from the Prospective Lynch Syndrome Database (PLSD) we 
reported 14 cases of sarcoma among 1808 prospectively observed tumors in 6350 carriers of 
path_MMR variants with 51,646 follow up years (FUY) 1.
The PLSD is an international multi-center prospective observational study without a 
control group, in which we record cancers diagnosed in genetically confirmed carriers of class 4 
and 5 path_MMR variants undergoing long-term surveillance. Data on previous cancers are 
collected at inclusion. 
In the PLSD, the mean age at prospective diagnosis of OS (n=10) was 63 years (range, 32-
74) and of STS (n=4) 62 years (range, 57-71). More than half of sarcomas (57%, 8/14) occurred 
in path_MSH2 carriers even though they comprised only 40% of PLSD patients, 21% were in 
path_MLH1 (3/14), 14% in path_PMS2 (2/14) and 7% (1/14) in path_MSH6 carriers. The type of 
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path_MMR variants identified in OS and STS patients were mainly predicted to cause missense 
changes (57%, 8/14), followed by deletions (4/14) and predicted splicing changes (2/14). Eight of 
14 patients (57%) were male.
Comparing the prospectively observed incidence of OS in the PLSD (21 per 100,000 FUY) 
to the worldwide general population incidence reported by Mirabello et al. showed a 50–63-fold 
relative incidence in LS 2. This is particularly striking as OS is primarily a cancer of childhood and 
adolescence, while in the PLSD, prospective observation is limited to ages 25–80 years 1.  
Cumulative incidence at 75 years (95% confidence interval) was 0.73% (0 – 1.56), 4.24% (0.54-
7.93), 0 and 1.57% (0-4.63) in path_MLH1, path_MSH2, path_MSH6 and path_PMS2 carriers, 
respectively, which for path_MSH2 carriers was significantly higher than the 0.1% population 
cumulative incidence at 75 years (p < 0.05) 3,4. Lifetime risk of OS in path_MSH2 carriers based 
on this comparison would be 42.4-fold (5.4 to 79.3) that of the general population.
In addition to the 14 prospectively observed sarcomas in the PLSD, 16 further patients had 
been affected by sarcoma before or at their inclusion: 5 with OS and 11 with STS, with mean ages 
at diagnosis of 48.2 (range, 4-64) and 35.1 (range, 24-54) years, respectively. Again, path_MSH2 
carriers were the most frequently affected (50%, 8/16), followed by path_MLH1 carriers (38%, 
6/16). Regarding the type of path_MMR variants identified in these patients, predicted missense 
changes were most common (7/16), followed by splicing (5/16) and deletion variants (4/16). 
Regarding gender, equal numbers of females (8) and males (8) were affected.
There is a paucity of studies linking OS and LS, even though MMR deficiency (dMMR) is 
seen very frequently in OS. In one previous study, loss of expression of MSH2/MSH6 was 
observed in 81% (54/67) of OS and was associated with better prognosis 5. By contrast, in another 
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retrospective study of 304 sarcomas that included only one case of OS, dMMR was confirmed in 
only 2.3% (7/304), and LS was diagnosed in one of these (14%) 6. 
A more recent study found that 6% (45/785) of STS had a microsatellite instability high 
(MSI-H) or intermediate (MSI-I) signature, and this was concordant with dMMR evaluated by 
immunohistochemistry. Two of the 45 cases (4.4%) had LS 7. Most recently, MSH2 was reported 
as one of a small number of genes that showed a significantly higher burden of pathogenic or likely 
pathogenic variants in European OS patients compared to controls (0.4%, 3 of 732 patients) 8.
We conclude that the incidence of OS in LS patients is significantly increased compared 
to the general population. We suggest that osteosarcoma is part of the LS spectrum in adults and 
seems to be associated particularly with the path_MSH2 genotype. The association of STS with 
path_MMR variants is currently less clear, although there are case reports on young LS carriers 
with soft tissue sarcomas 9,10.
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List of abbreviations
dMMR: MMR deficiency 
FUY: Follow up years
LS: Lynch syndrome
MMR: Mismatch repair
MSI-H: microsatellite instability high 
MSI-I: microsatellite instability intermediate 
OS: Osteosarcoma
path_MLH1: Pathogenic (disease-causing) variants of the MLH1 gene
path_MSH2: Pathogenic (disease-causing) variants of the MSH2 gene
path_MSH6: Pathogenic (disease-causing) variants of the MSH6 gene
path_PMS2: Pathogenic (disease-causing) variants of the PMS2 gene
PLSD: Prospective Lynch Syndrome Database
SFT: Soft tissue sarcoma
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